SynthesisMolecular diagnosis & therapy2018
Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.
Synthesis in Molecular diagnosis & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 8 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Pooled it
- Forkhead box F2 as a novel prognostic biomarker and potential therapeutic target in human cancers prone to bone metastasis: a meta-analysis.The Journal of international medical research · 2021Pooled it
- Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2020Pooled it
- Prognostic Significance of FOXC1 in Various Cancers: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2019Pooled it
- Pooled it
- Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis.Cells · 2019Pooled it
- Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma.PloS one · 2019Pooled it
- Review
- Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma: The UNC Chapel Hill Method.The American journal of surgical pathology · 2026Article
- Biocompatible exosomes derived fromRegenerative biomaterials · 2025Article
- Review
- Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- Article
- Computational and Bioinformatics Methods for MicroRNA Gene Prediction.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Study on the Mechanism of miR-125b-5p Affecting Melanocyte Biological Behavior and Melanogenesis in Vitiligo through Regulation of MITF.Disease markers · 2022Article
- Review
- The Prognostic Role of Micro-RNAs in Head and Neck Cancers: An Umbrella Review.Journal of personalized medicine · 2021Review
- microRNAs in the Regulation of Melanogenesis.International journal of molecular sciences · 2021Review
- Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma is the most aggressive and deadly form of skin cancer. The molecular variability involving microRNA (miRNA) expression plays a significant role in melanogenesis, which leads to poor prognostic effects in melanoma. Since there is a scarcity of comprehensive data on the prognostic role of miRNAs in melanoma patients, this study focuses on filling this knowledge gap through a systematic review and meta-analysis.
methodsThe included studies were extracted from several bibliographic databases between 2012 and 2018 using multiple keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The hazard ratios (HRs) and 95% confidence intervals (CIs) for different survival endpoints were compared to the high and low expression levels of miRNAs. The mean effect size of HR values was estimated using a random-effects model of meta-analysis. Inverted funnel plot symmetry was used to assess publication bias. Subgroup analysis was carried out individually for multiple miRNAs across different studies.
resultsA total of 24 studies across eight countries were included, of which 16 studies were eligible for meta-analysis. Twenty-five miRNA expression levels were studied from 2669 melanoma patients to estimate the association between the prognostic role of miRNAs and survival outcome in these 16 studies. The overall pooled effect size (HR) for up- and downregulated miRNAs was 1.043 (95% CI 0.921-1.181; p = 0.506), indicating that the miRNA expression increased the likelihood of death in melanoma patients by 4.3%. Subgroup analysis for miRNA10b, miRNA16 and miRNA21 showed a poor prognosis. The quality assessment revealed that 16 studies were good quality and eight studies were of fair quality.
conclusionThis is one of the first pooled meta-analysis studies on the role of miRNAs in the prognosis of melanoma. Our findings are inconclusive but suggest that miRNA expression could predict poor survival in melanoma patients. Therefore, miRNA expression could act as promising prognostic marker for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.